suzetrigine VX-548
Selected indexed studies
- VX-548 in the treatment of acute pain. (Pain Manag, 2024) [PMID:39552600]
- Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. (Anesthesiology, 2025) [PMID:40117446]
- Sensory neuron sodium channels as pain targets; from cocaine to Journavx (VX-548, suzetrigine). (J Gen Physiol, 2025) [PMID:40294084]
_Worker-drafted node — pending editorial review._
Connections
suzetrigine VX-548 is a side effect of
Sources
- Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. (2025) pubmed
- VX-548 in the treatment of acute pain. (2024) pubmed
- Sensory neuron sodium channels as pain targets; from cocaine to Journavx (VX-548, suzetrigine). (2025) pubmed
- Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective Na(V)1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain. (2025) pubmed
- Suzetrigine (VX-548): Bidding goodbye to opioids: The latest oral non-opioid analgesic for acute pain. (2025) pubmed
- State-Dependent Inhibition of Nav1.8 Sodium Channels by VX-150 and VX-548. (2024) pubmed
- Suzetrigine: First Approval. (2025) pubmed
- Suzetrigine, a Non-Opioid Na(V)1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain. (2025) pubmed
- Suzetrigine (VX-548) exhibits activity-dependent effects on human dorsal root ganglion neurons with differential pain etiology. (2026) pubmed
- Journavx (suzetrigine). (2025) pubmed